Alnylam Pharmace. buy BMO Capital Markets
Summary
This prediction ended on 28.03.25 with a price of €247.40. The BUY prediction by BMO_Capital_Markets for Alnylam Pharmace. saw massive gains of 74.96%. BMO_Capital_Markets has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. BMO_Capital_Markets has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | -2.939% | -2.939% | 13.932% |
| iShares Core DAX® | -1.499% | 7.705% | 5.243% |
| iShares Nasdaq 100 | 1.380% | 16.275% | 36.094% |
| iShares Nikkei 225® | -1.992% | 13.113% | 40.183% |
| iShares S&P 500 | 0.345% | 10.816% | 26.473% |
Comments by BMO_Capital_Markets for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.
Current prediction by BMO_Capital_Markets for Alnylam Pharmace.
Stopped prediction by BMO_Capital_Markets for Alnylam Pharmace.
Alnylam Pharmace.
05.09.25
05.09.26
09:57
Alnylam Pharmace.
24.06.24
24.06.25
25.06.25

